每经AI快讯，有投资者在投资者互动平台提问：（五）丰富民生领域应用场景 医疗卫生领域。推动大 数据、物联网、脑机接口等新一代信息技术及医疗机器人等智能设备集成应用，创新健康咨询、问诊指 引、辅助诊断、远程医疗、用药审核等医疗应用场景。 养老助残托育领域。创新服务机器人、智能可 穿戴设备、远程终端服务系统、在线家庭医生药师等应用场景，打造科技助残、家政服务、托育照护、 康复医疗、健康服务等相结合的生活服务场景。 贵司在这方面有什么产品？ （记者 曾健辉） 爱朋医疗（300753.SZ）11月13日在投资者互动平台表示，您好，公司在医疗卫生领域积极推动新一代 信息技术的应用，尤其在脑机接口技术方面，公司推出了顽固性失眠麻醉治疗系统，该系统针对顽固性 失眠麻醉睡眠诊疗临床需求而设计；多模态ADHD行为训练系统，采用科学脑电监测、多模态干预训练 等方式，帮助儿童逐步改善多动及注意缺陷行为，提升专注力。在养老助残托育领域，公司通过参股常 州瑞神安，布局了脑神经调控及颅内植入电极等医疗器械产品的研发、生产及销售，包括一次性使用颅 内脑电极（SEEG）、植入式迷走神经刺激器（VNS）、植入式可充电脊髓刺激器（SCS）及植入 ...

Financial Performance - The company reported a significant improvement in operating cash flow, with a year-on-year increase of 300.52% [2] - Revenue from the cardiovascular interventional business reached 1.239 billion, a growth of 7.57% year-on-year [2] - The overall revenue and profit for the first half of the year remained stable compared to the previous year [2] Business Segments Medical Devices - The in vitro diagnostics and surgical anesthesia segments experienced slight declines in revenue due to increased competition and procurement rhythms [2] - The skin care business aims for sales of 500-600 million in 2026, with a net profit margin of 45-50% [3] Innovative Drugs - The innovative drug segment is the largest in terms of R&D investment, focusing on metabolic diseases [4] - The company is optimistic about the potential of its innovative drugs, particularly in weight management and metabolic disorders [4] Strategic Adjustments - The company has undergone organizational restructuring to stabilize its performance after a period of significant fluctuations [2] - Future growth is expected to be driven by strategic emerging business segments, including dermatology and innovative drugs [2] Market Strategy - The company plans to maintain a sales expense ratio below 20% for its medical aesthetics products, focusing on scientific and cost-effective marketing strategies [8] - The pricing strategy for the "童颜针" (youthful needle) series aims to capture a broader market by offering competitive pricing [15] Regulatory and Competitive Landscape - The company anticipates a reduction in prices for drug-coated balloons due to procurement policies, which may increase market penetration [9] - The competitive landscape for GLP-1 drugs is intensifying, but the company remains confident in its product competitiveness [20] Future Outlook - Analysts project a net profit of around 1 billion for the current year, with a stable outlook for the formulation business [2] - The company aims for a revenue growth of 10-15% next year, driven by structural heart disease and pharmaceutical products [2]